Adverse events · 50‐ to 60‐year‐old women with metabolic syndrome
1 finding from 1 review
Cramp severity (0 to 10 VAS; higher = more pain) (after 6 weeks) · 50‐ to 60‐year‐old women with metabolic syndrome
1 finding from 1 review
Proportion of participants experiencing cramps · 50‐ to 60‐year‐old women with metabolic syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · 50‐ to 60‐year‐old women with metabolic syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of sleep · 50‐ to 60‐year‐old women with metabolic syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Activities of daily living · 50‐ to 60‐year‐old women with metabolic syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival · EGFR M+ patients with NSCLC
Gefitinib showed no clear difference in overall survival compared with pemetrexed + carboplatin with pemetrexed maintenance (moderate certainty).
1 finding from 1 review
Progression‐free survival · EGFR M+ patients with NSCLC
Gefitinib probably leads to lower progression‐free survival compared with pemetrexed + carboplatin with pemetrexed maintenance (moderate certainty).
1 finding from 1 review
Overall survival: Median length of · people with metastatic breast cancer
Capecitabine‐containing regimens showed no clear difference in overall survival (OS)median compared with chemotherapy regimens without capecitabine (high certainty).
1 finding from 1 review
OS: hormone receptor‐positivemedian · people with metastatic breast cancer
Capecitabine‐containing regimens showed no clear difference in OS: hormone receptor‐positivemedian compared with chemotherapy regimens without capecitabine (high certainty).
1 finding from 1 review
OS: hormone receptor‐negativemedian · people with metastatic breast cancer
Capecitabine‐containing regimens showed no clear difference in OS: hormone receptor‐negativemedian compared with chemotherapy regimens without capecitabine (high certainty).
1 finding from 1 review
Progression‐free survival · people with metastatic breast cancer
Capecitabine‐containing regimens probably leads to lower progression‐free survival (PFS)median compared with chemotherapy regimens without capecitabine (moderate certainty).
1 finding from 1 review
PFS: hormone receptor‐positivemedian · people with metastatic breast cancer
Capecitabine‐containing regimens probably leads to lower PFS: hormone receptor‐positivemedian compared with chemotherapy regimens without capecitabine (moderate certainty).
1 finding from 1 review
PFS: hormone receptor‐negativemedian · people with metastatic breast cancer
Capecitabine‐containing regimens showed no clear difference in PFS: hormone receptor‐negativemedian compared with chemotherapy regimens without capecitabine (moderate certainty).
1 finding from 1 review
Objective response rate · people with metastatic breast cancer
Capecitabine‐containing regimens showed no clear difference in objective response rate compared with chemotherapy regimens without capecitabine (moderate certainty).
1 finding from 1 review
Quality of life · people with metastatic breast cancer
1 finding from 1 review
Proportion of children who successfully completed neurodiagnostic procedure without interruption by the child awakening · children undergoing neurodiagnostic procedures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of children who required a further dose of either the same sedative agent or the addition of a different sedative agent · children undergoing neurodiagnostic procedures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to adequate sedation (minutes or as measured by specific validated scales such as the Ramsay Sedation Score) · children undergoing neurodiagnostic procedures
1 finding from 1 review
Proportion of children with inadequate level of sedation (Ramsay score below 4) · children undergoing neurodiagnostic procedures
Chloral hydrate oral (70 mg/kg) may leads to lower proportion of children with inadequate level of sedation (Ramsay… compared with promethazine oral (1 mg/kg) (low certainty).
1 finding from 1 review